| Next 10 |
MYGN News and Press, Myriad Genetics Inc.
-
The FDA approves Myriad Genetics' (NASDAQ: MYGN ) BRACAnalysis CDx test and Roche ( OTCQX:RHHBY ) unit Foundation Medicine's FoundationOne CDx test for use as a companion diagnostics to identify suitable metastatic castration-resistant prostate cancer (mCRPC) pat...
-
SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ® test for use as a compani...
-
Cancer diagnostic leader Exact Sciences (NASDAQ: EXAS) isn't having the best of years, and not just because of the COVID-19 pandemic. In February, the company announced it was selling approximately $1 billion in senior convertible notes to raise money. These notes will carry an annual i...
-
Myriad Receives the FDA Approval for Testing Ovarian Cancer Myriad Genetics ( MYGN ) announced that the FDA has given green signal to its myChoice CDx test to be used as a companion diagnostic for the identification of advanced ovarian cancer patients. The company stated that the device...
-
SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx ® test for use as a companion di...
-
The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2020 Q3 earnings Read more ...
-
Image source: The Motley Fool. Myriad Genetics Inc (NASDAQ: MYGN) Q3 2020 Earnings Call May 5, 2020 , 4:30 p.m. ET Operator Continue reading
-
Myriad Genetics, Inc. (MYGN) Q3 2020 Results Conference Call May 05, 2020 04:30 PM ET Company Participants Scott Gleason - Vice President-Investor Relations Bryan Riggsbee - Interim President and Chief Executive Officer Conference Call Participants Westley Dupray - SVB Leerin...
-
Myriad Genetics (NASDAQ: MYGN ): Q3 Non-GAAP EPS of -$0.08 misses by $0.09 ; GAAP EPS of -$1.55 misses by $1.28 . More news on: Myriad Genetics, Inc., Earnings news and commentary, Consumer stocks news, Read more ...
-
Total Third-Quarter Revenues of $164.0 Million Third-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecula...
Stock Information
MENU
MYGN
MYGN Quote
MYGN Short
MYGN News
MYGN Articles
MYGN Message Board
Get MYGN Alerts
News, Short Squeeze, Breakout and More Instantly...
RECENT MYGN NEWS
-
The FDA approves Myriad Genetics' (NASDAQ: MYGN ) BRACAnalysis CDx test and Roche ( OTCQX:RHHBY ) unit Foundation Medicine's FoundationOne CDx test for use as a companion diagnostics to identify suitable metastatic castration-resistant prostate cancer (mCRPC) pat...
-
SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ® test for use as a compani...
-
Cancer diagnostic leader Exact Sciences (NASDAQ: EXAS) isn't having the best of years, and not just because of the COVID-19 pandemic. In February, the company announced it was selling approximately $1 billion in senior convertible notes to raise money. These notes will carry an annual i...
